Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, ...
STOCKHOLM, May 6, 2024 /PRNewswire/ --Calliditas Therapeutics AB(Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in …